|
1
|
Ferlay J, Héry C, Autier P and
Sankaranarayanan R: Global burden of breast cancer. Breast cancer
epidemiology. Springer; pp. 1–19. 2010
|
|
2
|
Riaz M, van Jaarsveld MT, Hollestelle A,
Prager-van der Smissen WJ, Heine AA, Boersma AW, Liu J, Helmijr J,
Ozturk B, Smid M, et al: miRNA expression profiling of 51 human
breast cancer cell lines reveals subtype and driver
mutation-specific miRNAs. Breast Cancer Res. 15:R332013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization: World Cancer
Report. 2014
|
|
4
|
Eifel P, Axelson JA, Costa J, Crowley J,
Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M,
Kornblith AB, et al: National institutes of health consensus
development conference statement: Adjuvant therapy for breast
cancer, november 1-3, 2000. J Natl Cancer Inst. 93:979–989. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blum RH and Carter SK: Adriamycin. A new
anticancer drug with significant clinical activity. Ann Intern Med.
80:249–259. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen JS, Agarwal N and Mehta K:
Multidrug-resistant MCF-7 breast cancer cells contain deficient
intracellular calcium pools. Breast Cancer Res Treat. 71:237–247.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herman J, Mangala L and Mehta K:
Implications of increased tissue transglutaminase (TG2) expression
in drug-resistant breast cancer (MCF-7) cells. Oncogene.
25:3049–3058. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roberti A, La Sala DL and Cinti C:
Multiple genetic and epigenetic interacting mechanisms contribute
to clonally selection of drug-resistant tumors: Current views and
new therapeutic prospective. J Cell Physiol. 207:571–581. 2006.
View Article : Google Scholar
|
|
9
|
Duesberg P, Li R, Sachs R, Fabarius A,
Upender MB and Hehlmann R: Cancer drug resistance: The central role
of the karyotype. Drug Resist Updat. 10:51–58. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fojo T: Multiple paths to a drug
resistance phenotype: Mutations, translocations, deletions and
amplification of coding genes or promoter regions, epigenetic
changes and microRNAs. Drug Resist Updat. 10:59–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sevignani C, Calin GA, Siracusa LD and
Croce CM: Mammalian microRNAs: A small world for fine-tuning gene
expression. Mamm Genome. 17:189–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spizzo R, Almeida MIE, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shore AN, Herschkowitz JI and Rosen JM:
Noncoding RNAs involved in mammary gland development and
tumorigenesis: There's a long way to go. J Mammary Gland Biol
Neoplasia. 17:43–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan Z, Mao W, Bao Y, Zhang M, Su X and Xu
X: The long noncoding RNA CASC9 regulates migration and invasion in
esophageal cancer. Cancer Med. 5:2442–2447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song P, Jiang B, Liu Z, Ding J, Liu S and
Guan W: A three-lncRNA expression signature associated with the
prognosis of gastric cancer patients. Cancer Med. 6:1154–1164.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su X, Li G and Liu W: The long noncoding
RNA cancer susceptibility candidate 9 promotes nasopharyngeal
carcinogenesis via stabilizing HIF1α. DNA Cell Biol. 36:394–400.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chekhun VF, Lukyanova NY, Kovalchuk O,
Tryndyak VP and Pogribny IP: Epigenetic profiling of
multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals
novel hyper- and hypomethylated targets. Mol Cancer Ther.
6:1089–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hoffmeyer S, Burk O, Von Richter O, Arnold
HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I,
Eichelbaum M, et al: Functional polymorphisms of the human
multidrug-resistance gene: Multiple sequence variations and
correlation of one allele with P-glycoprotein expression and
activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang B, Zhang Y, Liang R, Gao Z, Sun D and
Wang L: RNAi-mediated EZH2 depletion decreases MDR1 expression and
sensitizes multidrug-resistant hepatocellular carcinoma cells to
chemotherapy. Oncol Rep. 29:1037–1042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou W, Wang J, Man WY, Zhang QW and Xu
WG: siRNA silencing EZH2 reverses cisplatin-resistance of human
non-small cell lung and gastric cancer cells. Asian Pac J Cancer
Prev. 16:2425–2430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Liu G, Lin C, Liao G and Tang B:
Silencing the EZH2 gene by RNA interference reverses the drug
resistance of human hepatic multidrug-resistant cancer cells to
5-Fu. Life Sci. 92:896–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao W, Wu W, Shi F, Chen X, Wu L, Yang K,
Tian F, Zhu M, Chen G, Wang W, et al: Integrated analysis of long
noncoding RNA and coding RNA expression in esophageal squamous cell
carcinoma. Int J Genomics. 2013:4805342013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shang C, Sun L, Zhang J, Zhao B, Chen X,
Xu H and Huang B: Silence of cancer susceptibility candidate 9
inhibits gastric cancer and reverses chemoresistance. Oncotarget.
8:15393–15398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visser HP, Gunster MJ, Kluin-Nelemans HC,
Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP: The
Polycomb group protein EZH2 is upregulated in proliferating,
cultured human mantle cell lymphoma. Br J Haematol. 112:950–958.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raman JD, Mongan NP, Tickoo SK, Boorjian
SA, Scherr DS and Gudas LJ: Increased expression of the polycomb
group gene, EZH2, in transitional cell carcinoma of the bladder.
Clin Cancer Res. 11:8570–8576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Collett K, Eide GE, Arnes J, Stefansson
IM, Eide J, Braaten A, Aas T, Otte AP and Akslen LA: Expression of
enhancer of zeste homologue 2 is significantly associated with
increased tumor cell proliferation and is a marker of aggressive
breast cancer. Clin Cancer Res. 12:1168–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Callaghan R, Luk F and Bebawy M:
Inhibition of the multidrug resistance P-glycoprotein: Time for a
change of strategy? Drug Metab Dispos. 42:623–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rahbari NN, Mehrabi A, Mollberg NM, Müller
SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma:
Current management and perspectives for the future. Ann Surg.
253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
